Carbocisteine

Suppliers

Names

[ CAS No. ]:
638-23-3

[ Name ]:
Carbocisteine

[Synonym ]:
EINECS 211-327-5
Carbocysteine
MFCD00002614
Loviscol
Thiodril
Alanine, 3-((carboxymethyl)thio)-, L-
3-(Carboxymethylthio)-L-alanine
L-Carbocisteine
Muciclar
Fluifort
Mucocis
L-Cysteine, S- (carboxymethyl)-
S-Carboxymethylcysteine
3-[(Carboxymethyl)thio]-L-alanine
L-Cysteine, S-(carboxymethyl)-
carbocisteine
Carbocistein
Mucodyne
Transbronchin
Reomucil
S-(Carboxymethyl)-L-cysteine
Rhinathiol
S-Carboxymethyl-L-cysteine
Lisomucil
carbocisteine API

Chemical & Physical Properties

[ Density]:
1.5±0.1 g/cm3

[ Boiling Point ]:
417.3±45.0 °C at 760 mmHg

[ Melting Point ]:
208-213 °C (dec.)

[ Molecular Formula ]:
C5H9NO4S

[ Molecular Weight ]:
179.194

[ Flash Point ]:
206.2±28.7 °C

[ Exact Mass ]:
179.025223

[ PSA ]:
125.92000

[ LogP ]:
0.32

[ Vapour Pressure ]:
0.0±2.1 mmHg at 25°C

[ Index of Refraction ]:
1.588

[ Water Solubility ]:
SOLUBLE IN COLD WATER

MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
AY4342000
CHEMICAL NAME :
Alanine, 3-((carboxymethyl)thio)-, L-
CAS REGISTRY NUMBER :
638-23-3
BEILSTEIN REFERENCE NO. :
1725012
LAST UPDATED :
199707
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C5-H9-N-O4-S
MOLECULAR WEIGHT :
179.21
WISWESSER LINE NOTATION :
QVYZ1S1VQ -L

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
>15 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YAKUD5 Gekkan Yakuji. Pharmaceuticals Monthly. (Yakugyo Jihosha, Inaoka Bldg., 2-36 Jinbo-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1959- Volume(issue)/page/year: 24,1705,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
7800 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,190,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
10300 mg/kg
TOXIC EFFECTS :
Behavioral - ataxia
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 32,993,1981
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
8400 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,190,1982
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1433 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
YKKZAJ Yakugaku Zasshi. Journal of Pharmacy. (Nippon Yakugakkai, 2-12-15 Shibuya, Shibuya-ku, Tokyo 150, Japan) No.1- 1881- Volume(issue)/page/year: 94,1419,1974
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
9 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,190,1982 ** OTHER MULTIPLE DOSE TOXICITY DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
11250 mg/kg/30D-I
TOXIC EFFECTS :
Blood - changes in erythrocyte (RBC) count Blood - changes in platelet count Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
REFERENCE :
YKYUA6 Yakkyoku. Pharmacy. (Nanzando, 4-1-11, Yushima, Bunkyo-ku, Tokyo, Japan) V.1- 1950- Volume(issue)/page/year: 32,993,1981 ** REPRODUCTIVE DATA **
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
625 mg/kg
SEX/DURATION :
female 17-21 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - physical
REFERENCE :
KSRNAM Kiso to Rinsho. Clinical Report. (Yubunsha Co., Ltd., 1-5, Kanda Suda-Cho, Chiyoda-ku, KS Bldg., Tokyo 101, Japan) V.1- 1960- Volume(issue)/page/year: 13,1311,1979

Safety Information

[ Hazard Codes ]:
Xi

[ Risk Phrases ]:
36/37/38

[ Safety Phrases ]:
S24/25

[ RIDADR ]:
NONH for all modes of transport

[ WGK Germany ]:
2

[ RTECS ]:
AY4342000

[ HS Code ]:
2930909090

Synthetic Route

Precursor & DownStream

Precursor

  • L-cysteine
  • Sodium chloroacetate
  • Iodoacetic acid
  • L-Cystine
  • DL-Cysteine Hydrochloride
  • 3-Chloro-L-alanine
  • Mercaptoacetic acid
  • Chloroacetic acid
  • O-acetyl-L-serine
  • UNII:48431VN59G

DownStream

  • L-Cysteine,N-benzoyl-S-(2-methoxy-2-oxoethyl)-, methyl ester
  • L-Cysteine,N-benzoyl-S-(carboxymethyl)-
  • L-Alanine,3-[(carboxymethyl)sulfinyl]-

Customs

[ HS Code ]: 2930909090

[ Summary ]:
2930909090. other organo-sulphur compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:30.0%

Articles

Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.

J. Med. Chem. 51 , 6740-51, (2008)

The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ...

Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.

Toxicol. Mech. Methods 18 , 217-27, (2008)

ABSTRACT Drug-induced phospholipidosis (PL) is a condition characterized by the accumulation of phospholipids and drug in lysosomes, and is found in a variety of tissue types. PL is frequently manifes...

Synthesis and biological evaluation of L-cysteine derivatives as mitotic kinesin Eg5 inhibitors.

Bioorg. Med. Chem. Lett. 17 , 3921-4, (2007)

Inhibition of Eg5 represents a novel approach for the treatment of cancer. Here, we report the synthesis and structure-activity relationship of S-trityl-L-cysteine (STLC) derivatives as Eg5 inhibitors...


More Articles


Related Compounds

  • Carbocisteine-13C3
  • (RS)-Carbocisteine
  • Carbocisteine Lactam
  • Carbocisteine sodium salt
  • Carbocisteine Lactam Sodium Salt
  • 2-[4-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]pent-4-enoic acid
  • [2-Methyl-4-(trifluoromethyl)-1,3-thiazol-5-yl]methanesulfonyl fluoride
  • 1'-(Propan-2-yl)spiro[bicyclo[2.2.1]heptane-2,2'-pyrrolidine]-3'-amine
  • 2-{[3-({[(9H-fluoren-9-yl)methoxy]carbonyl}amino)-4-methylpentanamido]methyl}-4-methylpentanoic acid
  • [5-iodo-1-(2,4,4-trimethylcyclopentyl)-1H-1,2,3-triazol-4-yl]methanamine
  • Methyl2-(2-oxopiperazin-1-yl)acetate,trifluoroaceticacid
  • 4-(aminomethyl)-1-cyclohexyl-1H-1,2,3-triazole-5-carboxylic acid
  • 6-Bromo-2-(methylthio)spiro[3H-indole-3,2a(2)-oxirane]
  • 1-(1-Aminocyclohex-3-en-1-yl)-3-fluoropropan-2-ol
  • (1S)-2-amino-1-(4,5,6,7-tetrahydro-1-benzothiophen-3-yl)ethan-1-ol
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.